The Wall Street Journal (online registration required): The U.S. Food and Drug Administration on Friday approved Pfizer Inc.’s Xalkori for treatment of a rare form of advanced non-small-cell lung cancer, making it the first therapy for the condition.
The drug’s use has been expanded to treat the roughly 1% of patients with advanced, or metastatic, non-small cell lung cancer whose tumors have an ROS-1 gene alteration, thought to lead to abnormal cells. Xalkori, or crizotinib, is the first..
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now